Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Leonard

Showing results (61-70 of 686) with videos related to

Pageof 69
Sort By:
Expert Opinion on Therapeutic Targets|July 7, 2007
Novel therapeutic targets in mantle cell lymphomaPeter Martin, John P Leonard
Haematologica|May 18, 2023
Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade?Erin Mulvey, John P Leonard
MMW, Munchener Medizinische Wochenschrift|March 23, 1979
[Indications and limitations of surgery of the sympathetic nervous system (author's transl)]J L Fontaine, P Leonard
Human Genetics|January 1, 1979
Heritable fragile sites on human chromosomes. IV. Silver stainingG R Sutherland, P Leonard
Minerva Medica|October 31, 1979
[Arteriopathy. Indications and limitations of sympathectomy]J L Fontaine, P Leonard
Journal of Neurochemistry|July 1, 1996
Protein tyrosine kinase-mediated potentiation of currents from cloned NMDA receptorsC Chen, J P Leonard
Emergency Medicine Journal : EMJ|July 2, 2003
How do blood cultures sent from a paediatric accident and emergency department influence subsequent clinical management?P Leonard, T F Beattie
Journal of Fluorescence|September 17, 2005
Luminescent Eu(III) and Tb(III) complexes: developing lanthanide luminescent-based devicesJoseph P Leonard, Thorfinnur Gunnlaugsson
Clinical Lymphoma & Myeloma|November 15, 2006
Should all patients with indolent lymphoma be treated with rituximab maintenance therapy? An overview of the dataBiree Andemariam, John P Leonard
Cancer Treatment and Research|May 18, 2006
Mantle cell lymphoma: current concept in biology and treatmentJia Ruan, John P Leonard
Pageof 69

Showing results (61-70 of 686) with videos related to

Sort By:
Pageof 69
Expert Opinion on Therapeutic Targets|July 7, 2007
Novel therapeutic targets in mantle cell lymphomaPeter Martin, John P Leonard
Haematologica|May 18, 2023
Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade?Erin Mulvey, John P Leonard
MMW, Munchener Medizinische Wochenschrift|March 23, 1979
[Indications and limitations of surgery of the sympathetic nervous system (author's transl)]J L Fontaine, P Leonard
Human Genetics|January 1, 1979
Heritable fragile sites on human chromosomes. IV. Silver stainingG R Sutherland, P Leonard
Minerva Medica|October 31, 1979
[Arteriopathy. Indications and limitations of sympathectomy]J L Fontaine, P Leonard
Journal of Neurochemistry|July 1, 1996
Protein tyrosine kinase-mediated potentiation of currents from cloned NMDA receptorsC Chen, J P Leonard
Emergency Medicine Journal : EMJ|July 2, 2003
How do blood cultures sent from a paediatric accident and emergency department influence subsequent clinical management?P Leonard, T F Beattie
Journal of Fluorescence|September 17, 2005
Luminescent Eu(III) and Tb(III) complexes: developing lanthanide luminescent-based devicesJoseph P Leonard, Thorfinnur Gunnlaugsson
Clinical Lymphoma & Myeloma|November 15, 2006
Should all patients with indolent lymphoma be treated with rituximab maintenance therapy? An overview of the dataBiree Andemariam, John P Leonard
Cancer Treatment and Research|May 18, 2006
Mantle cell lymphoma: current concept in biology and treatmentJia Ruan, John P Leonard
Pageof 69